2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting immunotherapy agents in bladder cancer.
Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting immunotherapy agents in bladder cancer.
Right now, there is not a clear-cut option for immunotherapy in the treatment of bladder cancer. It is currently up to treating physicians’ preference.
Every other day there are new data, says Black, and the community is just going to have to wait until the dust settles for a definitive answer.
Related Content: